Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Orient Gene Biotech Co's OCF Margin % or its related term are showing as below:
SHSE:688298'
s OCF Margin % Range Over the Past 10 Years
Min: -200.64 Med: 14.86 Max: 54.83
Current: -16.68
During the past 10 years, the highest OCF Margin % of Zhejiang Orient Gene Biotech Co was 54.83%. The lowest was -200.64%. And the median was 14.86%.
SHSE:688298's OCF Margin % is ranked worse than 74.02% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.87
vs SHSE:688298: -16.68
Zhejiang Orient Gene Biotech Co OCF Margin % Related Terms
Zhejiang Orient Gene Biotech Co OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Orient Gene Biotech Co OCF Margin % Chart
SHSE:688298 vs ABT, SYK, MDT: OCF Margin % Comparison
For the Medical Devices subindustry, Zhejiang Orient Gene Biotech Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Orient Gene Biotech Co OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Orient Gene Biotech Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Orient Gene Biotech Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Orient Gene Biotech Co (SHSE:688298) has a OCF Margin % of -11.36% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. According to the industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #604 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 74%.
Is Zhejiang Orient Gene Biotech Co's OCF Margin % too high?
Zhejiang Orient Gene Biotech Co's current OCF Margin % is -11.36%. Based on the distribution chart, Zhejiang Orient Gene Biotech Co ranks #604 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zhejiang Orient Gene Biotech Co has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Orient Gene Biotech Co's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Orient Gene Biotech Co ranks #604 out of 816 companies for OCF Margin %. This places Zhejiang Orient Gene Biotech Co in the lower half of its industry. The industry median OCF Margin % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.87, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Zhejiang Orient Gene Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Orient Gene Biotech Co's current OCF Margin % is -11.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Orient Gene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co (SHSE:688298) is currently considered Possible Value Trap. The stock's GF Value™ is ¥30.81, compared to a current price of ¥17.87 — trading 42% below its estimated fair value. The current OCF Margin % is -11.36%. Zhejiang Orient Gene Biotech Co's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Zhejiang Orient Gene Biotech Co (SHSE:688298), the current OCF Margin % is -11.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Orient Gene Biotech Co (SHSE:688298) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Orient Gene Biotech Co stock appears to be undervalued.
The current stock price of ¥17.87 is trading 42% below its estimated GF Value™ of ¥30.81.
GuruFocus considers Zhejiang Orient Gene Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688298:
OCF Margin %: -11.36%
GF Value™: ¥30.81 vs. price of ¥17.87 (42% below fair value)
No single metric tells the full story. See the SHSE:688298 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Orient Gene Biotech Co Business Description
Zhejiang Orient Gene Biotech Co Ltd is engaged in production, research, development and sale of vitro diagnostic products. The company's products include Genetic diagnosis, Colloidal gold rapid diagnostic tests, Dry chemical strips (urinalysis), Bio-liquid diagnostic kits, Clinical test instruments, POCT time-resolved Fluor immunoassay Test kit (TRFI), and Raw materials.
51GF Score
Get the complete analysis for SHSE:688298
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688298 has been successfully added to your 
